Navigation Links
Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya
Date:10/7/2010

EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya™ (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis. Gilenya was approved by the US Food and Drug Administration (FDA) on September 21, 2010.

For people with MS and healthcare professionals seeking information about Gilenya, Novartis offers free programs to learn about educational resources, the availability of free starter product, and the details of our prescription and medical co-pay support program for eligible patients. People can visit www.Gilenya.com or call 877-408-4974 for information about:  

  • The Gilenya Support Program, which offers treatment information, educational resources, assistance scheduling medical assessments and prescription benefits investigation.
  • The option of free starter product once a prescription has been written to help ensure immediate access to treatment during the benefits investigation process.  Free samples are also being provided to physician's offices and are available through the Gilenya Support Program.
  • The Gilenya Prescription Co-Pay Support Program, which will cover a significant portion of prescription out-of-pocket costs for eligible patients with commercial health insurance.*  
  • The Gilenya Medical Co-Pay Support Program, which will reduce the out-of-pocket costs associated with Gilenya initiation for eligible patients who require certain tests before starting treatment.**
  • The Novartis Patient Assistance Program (PAP), which provides access to Gilenya at no cost for eligible patients who have no third-party coverage. This program is open to all US residents without pharmacy coverage whose income is less than 500% of the Federal Poverty Level. In 2009, the Novartis PAP provided free product valued at over $232 million to
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
    (Date:3/31/2015)... -- SCILEX Pharmaceuticals, Inc., a company engaged in the development ... pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, ... ITOCHU Corporation ( Tokyo : 8001; OTC-PINK: ... trading companies) in Japan , has ... closely with SCILEX as an advisor and development partner ...
    (Date:3/31/2015)... , March 31, 2015  SynCardia Systems, Inc. has ... (IDE) clinical study on the effective use of its ... The FDA approval will ... as 30 heart failure patients. Patients enrolled in this ... as a bridge to a donor heart transplant. ...
    Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
    ... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
    ... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
    Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
    (Date:3/31/2015)... April 01, 2015 Every day a ... (standard American diet) contains things banned in other countries, ... rockets every year. AlignLife Chiropractic & Natural Health Centers ... also their communities they can reduce the future development ... year each AlignLife clinic offers workshops at no charge ...
    (Date:3/31/2015)... (PRWEB) March 31, 2015 As the ... Fitness is pledging to have a mobile-friendly website online ... is part of Chunk Fitness’ continued commitment to bring ... growing user base. All of the same great fitness ... it will be substantially easier to read while browsing ...
    (Date:3/31/2015)... Cosmetic Town, one of the most ... enduring adding news to its site while it redesigns ... plastic surgery and cosmetic medicine better use and navigate ... sections, the Cosmetic Town community is tingling at its ... Town site navigation, News and Blog section, will feature ...
    (Date:3/31/2015)... In conjunction with the Asbestos ... the Mesothelioma Applied Research Foundation (Meso Foundation) announced ... complement its existing work in mesothelioma research, education, ... the Meso Foundation’s mission, we want to eliminate ... to asbestos, including mesothelioma,” said the Meso Foundation’s ...
    (Date:3/31/2015)... FL (PRWEB) March 31, 2015 ... Systems (ADS) is offering advice for buying from ... Equipment Dealers Association (NMEDA) is a nonprofit organization ... professionalism in the manufacturing and installation of mobility ... companies in the industry that consistently adhere to ...
    Breaking Medicine News(10 mins):Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2
    ... research has identified a neuronal mechanism that our ... separate places and experiences. ,The ... with colleagues at the Massachusetts Institute of Technology ... as well as for the perplexity and uncertainty ...
    ... Following reports of irruption of legionnaires outbreak in Melbourne, ... are being scoured to locate the source ... and confirmed to be suffering from the legionnaires. ... pneumonia and it is caused by the bacterium ...
    ... According to a new study published in the American Journal ... cancer. Key milk nutrients, calcium and vitamin D, may ... the risk for cancer in women by at least 60 ... one thousand women over the age of 55 in one ...
    ... directly observe cell migration -- in real time and in ... lead to strategies for controlling both normal growth and the ... movement of cells across space. ,"The stars of ... that literally crawl across the length of an egg chamber ...
    ... the deadly H5N1 strain of bird flu, raising to 35 the ... official said. ,John Jabbour, a WHO official in Cairo, ... whom he did not name, was in "very critical" condition. ... ,The girl had been in contact with poultry, he said. ...
    ... foods that are low in calorie density can promote healthy weight ... that are high in water and low in fat such ... are low in calorie density and provide few calories per bite. ... density allows people to eat satisfying portions of food, and this ...
    Cached Medicine News:Health News:Why We Feel a Sense of Dj Vu 2Health News:Legionnaires Outbreak in Australia 2Health News:Milk Nutrients may Keep Cancer at Bay. 2Health News:Scientists Observed Live Cell Migration 2Health News:Low Calorie Diet can Promote Healthy Weight Loss and Help Control Hunger 2
    ... The Codman ICP ... accurate measurements of intracranial ... parenchymal or intraventricular levels. ... electronically rather than through ...
    Penfield Dissector #3...
    Leroy scalp clips, sterile, disposable, plastic, infant size, ten clips/package....
    Raney clip applying forceps, length 6 1/4"....
    Medicine Products: